(Rac)-PROTAC PARP/EGFR ligand 1

Cat. No.: HY-141486: Fiche technique Instruction de manipulation
FAQs
Technical Support

(Rac)-PROTAC PARP/EGFR ligand 1 incorporates a ligand for PARP and EGFR , and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). (Rac)-PROTAC PARP/EGFR ligand 1 can be used in the synthesis of DP-C-4, which is CRBN-based dual PROTAC for simultaneous degradation of EGFR and PARP.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

(Rac)-PROTAC PARP/EGFR ligand 1 Chemical Structure

CAS No. : 2935073-36-0

Size		Stock
MOQ		Minimum order quantity
50 mg		Obtenir un devis
100 mg		Obtenir un devis
250 mg		Obtenir un devis
Other size		Obtenir un devis

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Other Forms of (Rac)-PROTAC PARP/EGFR ligand 1:

PROTAC PARP/EGFR ligand 1 Obtenir un devis

Recommandations en vedette

•Related Small Molecules:

•Related Proteins:

Activité biologique
Pureté et documentation
Références
Avis client

Description	(Rac)-PROTAC PARP/EGFR ligand 1 incorporates a ligand for PARP and EGFR , and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). (Rac)-PROTAC PARP/EGFR ligand 1 can be used in the synthesis of DP-C-4, which is CRBN-based dual PROTAC for simultaneous degradation of EGFR and PARP^[1].
Masse moléculaire	1020.52
Formule	C₅₃H₅₆ClF₂N₉O₈
CAS No.	2935073-36-0
SMILES	O=C1NN=C(CC2=CC=C(C(C(N3CCN(CC3)C(CCCCCNC(C(COCC#C)NC(CCCCCOC4=CC5=C(NC6=CC=C(C(Cl)=C6)F)N=CN=C5C=C4OC)=O)=O)=O)=O)=C2)F)C7=C1C=CC=C7
Livraison	Room temperature in continental US; may vary elsewhere.
Stockage	Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation	Fiche technique (263 KB) Instruction de manipulation (2659 KB)
Références	[1]. Mengzhu Zheng, et al. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. J Med Chem. 2021 May 26. [Content Brief]